Kevin Shannon

A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies.

Benjamin S Braun, Ophélia Maertens, Mila E McCurrach, 2017, Cancer research.

Biochemical and Functional Characterization of Germ Line KRAS Mutations

Gideon Bollag, Martin Zenker, Kevin Shannon, 2007, Molecular and Cellular Biology.

Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation.

Jianjun Yu, Yumin Dai, Janet Sim, 2013, Blood.

Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras.

Herbert Waldmann, Kevin M Haigis, Christian Hedberg, 2012, Blood.

Germline KRAS mutations cause Noonan syndrome

Kam Y. J. Zhang, Erik Sistermans, Kam Y J Zhang, 2006, Nature Genetics.

Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.

James Downing, Megan E McNerney, Megan E. McNerney, 2013, Cancer discovery.

Oncogenes and cell proliferation.

Frank McCormick, Kevin Shannon, F. McCormick, 1994, Current opinion in genetics & development.

Targeting oncogenic Ras.

Kevin Shannon, K. Shannon, Ernesto Diaz-Flores, 2007, Genes & development.

Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation

Eric Legius, Jan Cools, Kevin Shannon, 2008, Human mutation.